R
Relmada Therapeutics D
D
RLMD
6.66000
USD
0.23
(3.50%)
Post Trading·6.66500USD+0.00500(+0.08%)
حجم التداول
98,545
الربح لكل سهم
-1
العائد الربحي
-
P/E
-6
حجم السوق
699,215,724
المقالات
العنوان: Relmada Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.







